XINTELA AB revenue breakdown overview

XINTELA AB revenue for the last year amounted to 4.21 M SEK, the most of which — 4.21 M SEK — came from its highest performing source at the moment, Medical Products within Stem Cell Therapy and Targeted Cancer Therapy, the year earlier bringing 78.00 k SEK. The greatest contribution to the revenue figure was made by Sweden — last year it brought XINTELA AB 4.21 M SEK, and the year before that — 78.00 k SEK.